Clinical Trials
17 trialsNCT04657120 2025-12-23
HYDRA
Leiden University Medical Center
Phase NA Completed
NCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT06457269 2024-11-27
EPLLMMRDC
North Sichuan Medical College
Phase NA Completed
NCT04996693 2023-11-22
On Dose Efficiency of Modern CT-scanners in Chest Scans
University Hospital Augsburg
Phase NA Completed
NCT02744092 2023-10-03
CANVAS
Alliance Foundation Trials, LLC.
Phase NA Completed
NCT04191928 2021-12-23
PAP-UP
Thomas Jefferson University
Phase 1 Completed
NCT04704349 2021-11-03
LISSE1
Centre Hospitalier Régional d'Orléans
Phase NA Completed
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT02073682 2019-03-06
Cancer Venous Thromboembolism (VTE)
Daiichi Sankyo
Phase 3 Completed
NCT02334007 2018-09-18
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
McMaster University
Phase 1/2 Completed
NCT02476526 2017-11-28
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
VA Greater Los Angeles Healthcare System
Phase 4 Completed
NCT00966277 2016-12-12
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
M.D. Anderson Cancer Center
Phase 4 Completed
NCT00320255 2016-08-16
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00773448 2015-07-07
SOME
Ottawa Hospital Research Institute
Phase NA Completed
NCT00967148 2014-10-22
PERI-OP
Ottawa Hospital Research Institute
Phase NA Completed
NCT00219973 2010-04-28
CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
Rovi Pharmaceuticals Laboratories
Phase 3 Completed
NCT00135876 2007-04-27
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
Ontario Clinical Oncology Group (OCOG)
Phase 3 Completed